EUVIMEDEUVIMED entdecken
VergleichsstudieRandomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

Tirzepatide 10 and 15 mg versus semaglutide 2.4 mg in people with obesity or overweight with type 2 diabetes: An indirect treatment comparison

Emily R Hankosky iD, Xuanyao He, Raleigh Malik, Julia Fraseur Brumm, Fangyu Wang, Anthony Niemeyer, Xiaotian M Zhang, W Timothy Garvey iD

Diabetes, Obesity and Metabolism · 2025-07 · 27 (7) · 3757-3765

DOI: 10.1111/dom.16401 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 05.05.2025. Verfasst von Emily R Hankosky und 7 weiteren Autor:innen. Beteiligte Einrichtung: Eli Lilly and Company, Indianapolis, Indiana, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Obesity, Overweight. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDDK NIH HHS, Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Tirzepatide and semaglutide demonstrated clinically meaningful weight reduction in people with obesity or overweight and type 2 diabetes (T2D) in SURMOUNT‐2 and STEP 2 clinical trials, respectively. In the absence of head‐to‐head trials, this study compared the efficacy of tirzepatide 10 and 15 mg with semaglutide 2.4 mg using an indirect treatment comparison. Materials and Methods Mean percent change in weight from baseline, weight reduction ≥5% and mean change in glycated haemoglobin (HbA1c [%]) were compared between tirzepatide 10/15 mg (week 72, SURMOUNT‐2) and semaglutide 2.4 mg (week 68, STEP 2) applying the Bucher method to the efficacy estimand. Sensitivity analyses included the use of matching‐adjusted indirect comparison, treatment regimen estimand and comparing study outcomes at 68 weeks.

Results

Tirzepatide 10 and 15 mg were associated with significantly greater mean percent weight reductions versus semaglutide (mean difference, 10 mg: 2.57%; 15 mg: 4.79%, p < 0.01). Tirzepatide 15 mg had significantly higher odds of achieving ≥5% weight reduction (odds ratio 15 mg: 1.76, 95% CI 1.04–2.97, p = 0.035; odds ratio 10 mg: 1.24, 95% CI 0.75–2.04, p = 0.407), and both tirzepatide doses were associated with significantly greater reductions in HbA1c (%) levels (mean difference, 10 mg: 0.47%; 15 mg: 0.56%, p < 0.001) than semaglutide. Sensitivity analyses were generally consistent with the primary analysis, exceptions including when power was reduced in the matching‐adjusted indirect comparison analyses and in the categorical weight reduction outcome.

Conclusions

This analysis suggested greater reductions in bodyweight and HbA1c (%) levels associated with tirzepatide 10 and 15 mg than with semaglutide 2.4 mg in people with obesity or overweight and T2D.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Glucagon-Like PeptidesObesityOverweightTirzepatideHypoglycemic AgentsHumansFemaleMaleMiddle AgedGlycated HemoglobinWeight LossTreatment OutcomeAdultAgedGlucagon-Like Peptide 1Semaglutide

Stichwörter der Autor:innen

indirect treatment comparisonobesitysemaglutidetirzepatidetype 2 diabetesweight reduction

Substanzen

Glucagon-Like PeptidesGlycated HemoglobinTirzepatideHypoglycemic AgentsGlucagon-Like Peptide 1Semaglutide

Autor:innen und Institutionen

  • Eli Lilly and Company, Indianapolis, Indiana, USA.
  • University of Alabama at Birmingham, Birmingham, Alabama, USA.

ORCID-Profile: Emily R Hankosky, W Timothy Garvey

Förderung

  • NIDDK NIH HHS
  • Eli Lilly and Company

Zitieren

APA

Hankosky, E. R., He, X., Malik, R., Fraseur Brumm, J., Wang, F., Niemeyer, A., Zhang, X. M., & Garvey, W. T. (2025). Tirzepatide 10 and 15 mg versus semaglutide 2.4 mg in people with obesity or overweight with type 2 diabetes: An indirect treatment comparison. Diabetes, Obesity and Metabolism, 27(7), 3757-3765. https://doi.org/10.1111/dom.16401

Vancouver

Hankosky ER, He X, Malik R, Fraseur Brumm J, Wang F, Niemeyer A, et al. Tirzepatide 10 and 15 mg versus semaglutide 2.4 mg in people with obesity or overweight with type 2 diabetes: An indirect treatment comparison. Diabetes, Obesity and Metabolism. 2025;27(7):3757-3765. doi:10.1111/dom.16401

BibTeX
@article{Hankosky2025,
  author = {Hankosky, Emily R and He, Xuanyao and Malik, Raleigh and Fraseur Brumm, Julia and Wang, Fangyu and Niemeyer, Anthony and Zhang, Xiaotian M and Garvey, W Timothy},
  title = {Tirzepatide 10 and 15 mg versus semaglutide 2.4 mg in people with obesity or overweight with type 2 diabetes: An indirect treatment comparison},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  volume = {27},
  number = {7},
  pages = {3757--3765},
  doi = {10.1111/dom.16401}
}
Kostenlos starten →